<DOC>
	<DOCNO>NCT00723775</DOCNO>
	<brief_summary>To compare plasma GSK706769 PK follow repeat administration GSK706769 QD without KALETRA ( LPV 400 mg/RTV 100mg ) q12h</brief_summary>
	<brief_title>GSK706769/KALETRA Drug-drug Interaction Study</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure Male female 18 50 year age . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : Is premenopausal female document bilateral tubal ligation , bilateral oophorectomy ( removal ovary ) , hysterectomy ; Is postmenopausal defined 12 month spontaneous amenorrhea . A follicle stimulate hormone ( FSH ) level perform confirm postmenopausal status . For study , FSH level &gt; 40 mlU/ml confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt , HRT discontinue 2 week subject rescreened , HRT suppress FSH . Following confirmation postmenopausal status , resume use HRT . Male subject must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication 14 day last dose medication . Body weight &gt; = 50 kg ( 110 lb . ) men &gt; =45 kg ( 99 lb ) woman BMI within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . As result medical interview , physical examination , screen investigation , Investigator considers subject unfit study . The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . Note : One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample treatment period . History regular use tobacco nicotinecontaining product within 3 month prior screen . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PCTA ) clinically significant cardiac disease . History/evidence clinically significant pulmonary disease . History significant renal hepatic disease . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . The subject receive GSK706769 previous clinical trial . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol . Note : `` Study '' `` investigational '' drug include GSK706769 Kaletra Where participation study would result donation blood blood product excess 500 mL within 56 day period . Note : include plasma donation . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject . Exclusion criterion screen ECG per protocol . Exclusion Criteria 24Hour Screening Holter per protocol ( conduct telemetry warrant finding telemetry ongoing repeat dose study ) :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>KALETRA</keyword>
	<keyword>GSK706769</keyword>
	<keyword>HIV</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>